Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Sprycel
SPRYCEL 20 mg film-coated tablets SPRYCEL 50 mg film-coated tablets SPRYCEL 70 mg film-coated tablets SPRYCEL 80 mg film-coated tablets SPRYCEL 100 mg film-coated tablets SPRYCEL 140 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-116685 · Präparat HOS-094467
Histamine-2 antagonists and proton pump inhibitors
Long-term suppression of gastric acid secretion by H2 antagonists or proton pump inhibitors (e.g.
famotidine and omeprazole) is likely to reduce dasatinib exposure. In a single-dose study in healthy
subjects, the administration of famotidine 10 hours prior to a single dose of SPRYCEL reduced
dasatinib exposure by 61%. In a study of 14 healthy subjects, administration of a single 100-mg dose
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T12:05:00Z · SHA-256 c065657005bf3f51d58db1cb5b29a1453d36e1fc897c0adb5e47ed684f07722e · Passage d2afa3fdf1bf0658557d2b5fa1b3cf6262d393daa417a1e89661e9fbd0270118 · Zeichen 1809–2253 im Abschnitt
Wechselwirkungen · Sprycel
SPRYCEL 20 mg film-coated tablets SPRYCEL 50 mg film-coated tablets SPRYCEL 70 mg film-coated tablets SPRYCEL 80 mg film-coated tablets SPRYCEL 100 mg film-coated tablets SPRYCEL 140 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-116687 · Präparat HOS-094467
11
of SPRYCEL 22 hours following a 4-day, 40-mg omeprazole dose at steady state reduced the AUC of
dasatinib by 43% and the Cmax of dasatinib by 42%. The use of antacids should be considered in place
of H2 antagonists or proton pump inhibitors in patients receiving SPRYCEL therapy (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T12:05:00Z · SHA-256 c065657005bf3f51d58db1cb5b29a1453d36e1fc897c0adb5e47ed684f07722e · Passage dfbb9f8ddb68648c620d00d3f7d5f243d0dc39e822c87707867be1d96eed84c3 · Zeichen 2306–2607 im Abschnitt
Wechselwirkungen · Sprycel
SPRYCEL 10 mg/mL powder for oral suspension · Abschnitt 4.5 · PDF-Seite 47
HOS-116739 · Präparat HOS-094467
Histamine-2 antagonists and proton pump inhibitors
Long-term suppression of gastric acid secretion by H2 antagonists or proton pump inhibitors (e.g.
famotidine and omeprazole) is likely to reduce dasatinib exposure. In a single-dose study in healthy
subjects, the administration of famotidine 10 hours prior to a single dose of SPRYCEL reduced
dasatinib exposure by 61%. In a study of 14 healthy subjects, administration of a single 100-mg dose
of SPRYCEL 22 hours following a 4-day, 40-mg omeprazole dose at steady state reduced the AUC of
dasatinib by 43% and the Cmax of dasatinib by 42%. The use of antacids should be considered in place
of H2 antagonists or proton pump inhibitors in patients receiving SPRYCEL therapy (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T12:05:00Z · SHA-256 c065657005bf3f51d58db1cb5b29a1453d36e1fc897c0adb5e47ed684f07722e · Passage 81210217abe1aa9b5fe84545a2638c76205c7db3f3be6c57c518505b88d5dc45 · Zeichen 1809–2551 im Abschnitt
Wechselwirkungen · Advagraf
Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 10–11
HOS-116802 · Präparat HOS-094481
10
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
Strong CYP3A4 inhibitors: May increase tacrolimus whole It is recommended that
antifungal agents (e.g., blood trough concentrations and concomitant use should be
ketoconazole, itraconazole, increase the risk of serious adverse avoided. If co-administration
posaconazole, voriconazole), reactions (e.g., nephrotoxicity, of a strong CYP3A4 inhibitor
the macrolide antibiotics neurotoxicity, QT prolongation) is unavoidable, consider
(e.g., telithromycin, which requires close monitoring omitting the dose of tacrolimus
troleandomycin, [see section 4.4]. the day the strong CYP3A4
clarithromycin, josamycin), Rapid and sharp increases in inhibitor is initiated. Reinitiate
HIV protease inhibitors tacrolimus levels may occur, as tacrolimus the next day at a
(e.g., ritonavir, nelfinavir, early as within 1-3 days after co- reduced dose based on
saquinavir), HCV protease administration, despite immediate tacrolimus blood
inhibitors (e.g., telaprevir, reduction of tacrolimus dose. concentrations. Changes in
boceprevir, and the Overall tacrolimus exposure may both tacrolimus dose and/or
combination of ombitasvir increase > 5 fold. When ritonavir dosing frequency should be
and paritaprevir with combinations are co-administered, individualized and adjusted as
ritonavir, when used with tacrolimus exposure may increase needed based on tacrolimus
and without dasabuvir), > 50 fold. Nearly all patients may trough concentrations, which
nefazodone, the require a reduction in tacrolimus should be assessed at initiation,
pharmacokinetic enhancer dose and temporary interruption of monitored frequently
cobicistat, and the kinase tacrolimus may also be necessary. throughout (starting within the
inhibitors idelalisib, The effect on tacrolimus blood first few days) and re-
ceritinib. concentrations may remain for evaluated on and after
Strong interactions have also several days after co-administration completion of the CYP3A4
been observed with the is completed. inhibitor. Upon completion,
macrolide antibiotic appropriate dose and dosing
erythromycin frequency of tacrolimus should
be guided by tacrolimus blood
concentrations. Monitor renal
function, ECG for QT
prolongation, and other side
effects closely.
Moderate or weak CYP3A4 May increase tacrolimus whole Monitor tacrolimus whole
inhibitors: blood trough concentrations and blood trough concentrations
antifungal agents (e.g., increase the risk of serious adverse frequently, starting within the
fluconazole, isavuconazole, reactions (e.g., neurotoxicity, QT first few days of co-
clotrimazole, miconazole), prolongation) [see section 4.4]. A administration. Reduce
the macrolide antibiotics rapid increase in tacrolimus level tacrolimus dose if needed [see
(e.g., azithromycin), calcium may occur. section 4.2]. Monitor renal
channel blockers (e.g., function, ECG for QT
nifedipine, nicardipine, prolongation, and other side
diltiazem, verapamil), effects closely.
amiodarone, danazol,
ethinylestradiol,
lansoprazole, omeprazole,
the HCV antivirals
elbasvir/grazoprevir and
glecaprevir/pibrentasvir, the
CMV antiviral letermovir,
and the tyrosine kinase
inhibitors nilotinib,
crizotinib and imatinib and
(Chinese) herbal remedies
containing extracts of
Schisandra sphenanthera
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) letermovir (HOS-090621) ceritinib (HOS-086215) josamycin (HOS-113844) diltiazem (HOS-086288) nefazodone (HOS-084519) elbasvir (HOS-108814) isavuconazole (HOS-085186) nifedipine (HOS-086289) nelfinavir (HOS-084520) nicardipine (HOS-090619) protease (HOS-085623) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) crizotinib (HOS-116818) cobicistat (HOS-088111) glecaprevir (HOS-086297) azithromycin (HOS-088112) clotrimazole (HOS-090574) calcium (HOS-085615) imatinib (HOS-110212) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) grazoprevir (HOS-108815) itraconazole (HOS-084516) saquinavir (HOS-084522) danazol (HOS-085473) fluconazole (HOS-087945) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) amiodarone (HOS-085596) paritaprevir (HOS-110301) tyrosine (HOS-108875) posaconazole (HOS-085622) nilotinib (HOS-086218) miconazole (HOS-115630) idelalisib (HOS-116811) omeprazole (HOS-085912) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage 871fa2c72a31ddd6873cbb2f1b3b0dd9ad898b46eba141ac32a052a178cc3bc9 · Zeichen 3910–8415 im Abschnitt
Wechselwirkungen · Isentress
ISENTRESS 400 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-119065 · Präparat HOS-094905
Co-administration of raltegravir with other agents that increase gastric pH (e.g., omeprazole and
famotidine) may increase the rate of raltegravir absorption and result in increased plasma levels of
raltegravir (see Table 1). Safety profiles in the subgroup of patients in Phase III trials taking proton
pump inhibitors or H2 antagonists were comparable with those who were not taking these antacids.
Therefore, no dose adjustment is required with use of proton pump inhibitors or H2 antagonists.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage 58c95c26ef8b07dab80595f47ddccd1a03de32f424e472ba71faed56abb23dc3 · Zeichen 3917–4413 im Abschnitt
Wechselwirkungen · Isentress
ISENTRESS 400 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-119086 · Präparat HOS-094905
8
Medicinal products by therapeutic Interaction Recommendations
area (mechanism, if known) concerning
co-administration
Other METAL CATION
Iron salts Expected: Given simultaneously iron salts
Raltegravir AUC are expected to reduce
raltegravir plasma levels;
taking iron salts at least two
(chelation of metal cations) hours from the administration
of raltegravir may allow to
limit this effect.
H2 BLOCKERS AND PROTON PUMP INHIBITORS
omeprazole raltegravir AUC ↑ 37 % No dose adjustment required
(raltegravir 400 mg Twice Daily) raltegravir C12 hr ↑ 24 % for raltegravir.
raltegravir Cmax ↑ 51 %
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): iron (HOS-085656) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage 567075ad7012294d77a6e8a178696a2bddb9ca89d644a4a44a2b5439f7dc4ff4 · Zeichen 12210–13461 im Abschnitt
Wechselwirkungen · Isentress
ISENTRESS 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 33
HOS-119168 · Präparat HOS-094905
(chelation of metal ions)
Other METAL CATION
Iron salts Expected: Given simultaneously iron salts
Raltegravir AUC are expected to reduce
raltegravir plasma levels;
taking iron salts at least two
(chelation of metal cations) hours from the administration
of raltegravir may allow to
limit this effect.
H2 BLOCKERS AND PROTON PUMP INHIBITORS
omeprazole raltegravir AUC ↑ 37%
(raltegravir 400 mg Twice Daily) raltegravir C12 hr ↑ 24%
raltegravir Cmax ↑ 51%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): iron (HOS-085656) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage 3cae5ee8d6550edce9a554886cf2a348c32a5fbe5d147a728aa1b34a4af1c807 · Zeichen 18161–19120 im Abschnitt
Wechselwirkungen · Isentress
ISENTRESS 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 33
HOS-119170 · Präparat HOS-094905
famotidine raltegravir AUC ↑ 44%
(raltegravir 400 mg Twice Daily) raltegravir C12 hr ↑ 6%
raltegravir Cmax ↑ 60% No dose adjustment required
for raltegravir (400 mg twice
(increased solubility) daily and 1,200 mg once daily).
gastric pH altering agents: Population PK analysis showed
proton pump inhibitors (e.g. that the effect of gastric pH
omeprazole), H2 blockers (e.g. altering agents on raltegravir
famotidine, ranitidine, cimitedine) pharmacokinetics was minimal
(8.8% decrease in relative
(raltegravir 1,200 mg) bioavailability), and was not
statistically or clinically
significant.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087) ranitidine (HOS-085660) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage 97d9041e14d1760340039cafb1421be56c85012a6d0a1120af6d345f6f984ba8 · Zeichen 19188–20158 im Abschnitt
Wechselwirkungen · Isentress
ISENTRESS 25 mg chewable tablets ISENTRESS 100 mg chewable tablets · Abschnitt 4.5 · PDF-Seite 55
HOS-119222 · Präparat HOS-094905
Co-administration of raltegravir with other agents that increase gastric pH (e.g., omeprazole and
famotidine) may increase the rate of raltegravir absorption and result in increased plasma levels of
raltegravir (see Table 3). Safety profiles in the subgroup of patients in Phase III trials taking proton
pump inhibitors or H2 antagonists were comparable with those who were not taking these antacids.
Therefore, no dose adjustment is required with use of proton pump inhibitors or H2 antagonists.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage e28a7d57ada622ec50b9854d97b7f5a2c051b44b34f824b11029979b6847e0b2 · Zeichen 3917–4413 im Abschnitt
Wechselwirkungen · Isentress
ISENTRESS 25 mg chewable tablets ISENTRESS 100 mg chewable tablets · Abschnitt 4.5 · PDF-Seite 57–58
HOS-119243 · Präparat HOS-094905
57
Medicinal products by therapeutic Interaction Recommendations
area (mechanism, if known) concerning
co-administration
Iron salts Expected: Given simultaneously iron salts
Raltegravir AUC are expected to reduce
raltegravir plasma levels;
taking iron salts at least two
(chelation of metal cations) hours from the administration
of raltegravir may allow to
limit this effect.
H2 BLOCKERS AND PROTON PUMP INHIBITORS
omeprazole raltegravir AUC ↑ 37 % No dose adjustment required
(raltegravir 400 mg Twice Daily) raltegravir C12 hr ↑ 24 % for raltegravir.
raltegravir Cmax ↑ 51 %
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): iron (HOS-085656) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage fed116cd0f83e48e99c83aa893bee160014baffbf7c571fc3c486ad959581517 · Zeichen 12240–13485 im Abschnitt
Wechselwirkungen · Isentress
ISENTRESS 100 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 79
HOS-119294 · Präparat HOS-094905
Co-administration of raltegravir with other agents that increase gastric pH (e.g., omeprazole and
famotidine) may increase the rate of raltegravir absorption and result in increased plasma levels of
raltegravir (see Table 3). Safety profiles in the subgroup of patients in Phase III trials taking proton
pump inhibitors or H2 antagonists were comparable with those who were not taking these antacids.
Therefore, no dose adjustment is required with use of proton pump inhibitors or H2 antagonists.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famotidine (HOS-112087) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage e28a7d57ada622ec50b9854d97b7f5a2c051b44b34f824b11029979b6847e0b2 · Zeichen 3916–4412 im Abschnitt
Wechselwirkungen · Isentress
ISENTRESS 100 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 82
HOS-119314 · Präparat HOS-094905
Other METAL CATION
Iron salts Expected: Given simultaneously iron salts
Raltegravir AUC are expected to reduce
raltegravir plasma levels;
taking iron salts at least two
(chelation of metal cations) hours from the administration
of raltegravir may allow to
limit this effect.
H2 BLOCKERS AND PROTON PUMP INHIBITORS
omeprazole raltegravir AUC ↑ 37 % No dose adjustment required
(raltegravir 400 mg Twice Daily) raltegravir C12 hr ↑ 24 % for raltegravir.
raltegravir Cmax ↑ 51 %
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): iron (HOS-085656) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage c7f817fef5d648e005b5ff6968d9c1edd76e3a721c910d62c5ea1d03ed1054c1 · Zeichen 12183–13182 im Abschnitt
Wechselwirkungen · Vimpat
Vimpat 50 mg film-coated tablets Vimpat 100 mg film-coated tablets Vimpat 150 mg film-coated tablets Vimpat 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-119442 · Präparat HOS-094947
Lacosamide does not inhibit or induce CYP2C19 and CYP3A4 to a clinically relevant extent.
Lacosamide did not affect the AUC of midazolam (metabolised by CYP3A4, lacosamide given
200 mg twice a day), but C max of midazolam was slightly increased (30 %). Lacosamide did not affect
the pharmacokinetics of omeprazole (metabolised by CYP2C19 and CYP3A4, lacosamide given
300 mg twice a day).
The CYP2C19 inhibitor omeprazole (40 mg once daily) did not give rise to a clinically significant
change in lacosamide exposure. Thus, moderate inhibitors of CYP2C19 are unlikely to affect systemic
lacosamide exposure to a clinically relevant extent.
Caution is recommended in concomitant treatment with strong inhibitors of CYP2C9 (e.g.
fluconazole) and CYP3A4 (e.g. itraconazole, ketoconazole, ritonavir, clarithromycin), which may lead
to increased systemic exposure of lacosamide. Such interactions have not been established in vivo, but
are possible based on in vitro data.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) lead (HOS-085592) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) ritonavir (HOS-084521) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T11:46:00Z · SHA-256 5f9684302e7c8a579e94d70f499a6979b21c5d712f752fe49c5607a3581bef64 · Passage 306c6e516bd92e26230e3ed678f84de0363304e5a11ec579daa8f9588f965831 · Zeichen 998–1964 im Abschnitt
Wechselwirkungen · Vimpat
Treatment initiation pack (in adolescents and children weighing 50 kg or more and adults only) Vimpat 50 mg film-coated tablets Vimpat 100 mg film-coated tablets Vimpat 150 mg film-coated tablets Vimpat 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 27
HOS-119477 · Präparat HOS-094947
Lacosamide does not inhibit or induce CYP2C19 and CYP3A4 to a clinically relevant extent.
Lacosamide did not affect the AUC of midazolam (metabolised by CYP3A4, lacosamide given
200 mg twice a day) but C max of midazolam was slightly increased (30 %). Lacosamide did not affect
the pharmacokinetics of omeprazole (metabolised by CYP2C19 and CYP3A4, lacosamide given
300 mg twice a day).
The CYP2C19 inhibitor omeprazole (40 mg once daily) did not give rise to a clinically significant
change in lacosamide exposure. Thus, moderate inhibitors of CYP2C19 are unlikely to affect systemic
lacosamide exposure to a clinically relevant extent.
Caution is recommended in concomitant treatment with strong inhibitors of CYP2C9 (e.g.
fluconazole) and CYP3A4 (e.g. itraconazole, ketoconazole, ritonavir, clarithromycin), which may lead
to increased systemic exposure of lacosamide. Such interactions have not been established in vivo but
are possible based on in vitro data.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) lead (HOS-085592) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) ritonavir (HOS-084521) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T11:46:00Z · SHA-256 5f9684302e7c8a579e94d70f499a6979b21c5d712f752fe49c5607a3581bef64 · Passage 09bdb85e3781a2bbf9800b7cbb7cfaaa50df0c6d9f79307fa9fb41425f2e39dc · Zeichen 998–1962 im Abschnitt
Wechselwirkungen · Vimpat
Vimpat 10 mg/ml syrup · Abschnitt 4.5 · PDF-Seite 49
HOS-119510 · Präparat HOS-094947
Lacosamide does not inhibit or induce CYP2C19 and CYP3A4 to a clinically relevant extent.
Lacosamide did not affect the AUC of midazolam (metabolised by CYP3A4, lacosamide given
200 mg twice a day) but C max of midazolam was slightly increased (30 %). Lacosamide did not affect
the pharmacokinetics of omeprazole (metabolised by CYP2C19 and CYP3A4, lacosamide given
300 mg twice a day).
The CYP2C19 inhibitor omeprazole (40 mg once daily) did not give rise to a clinically significant
change in lacosamide exposure. Thus, moderate inhibitors of CYP2C19 are unlikely to affect systemic
lacosamide exposure to a clinically relevant extent.
Caution is recommended in concomitant treatment with strong inhibitors of CYP2C9 (e.g.
fluconazole) and CYP3A4 (e.g. itraconazole, ketoconazole, ritonavir, clarithromycin), which may lead
to increased systemic exposure of lacosamide. Such interactions have not been established in vivo but
are possible based on in vitro data.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) lead (HOS-085592) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) ritonavir (HOS-084521) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T11:46:00Z · SHA-256 5f9684302e7c8a579e94d70f499a6979b21c5d712f752fe49c5607a3581bef64 · Passage 09bdb85e3781a2bbf9800b7cbb7cfaaa50df0c6d9f79307fa9fb41425f2e39dc · Zeichen 998–1962 im Abschnitt
Wechselwirkungen · Vimpat
Vimpat 10 mg/ml solution for infusion · Abschnitt 4.5 · PDF-Seite 70
HOS-119545 · Präparat HOS-094947
Lacosamide does not inhibit or induce CYP2C19 and CYP3A4 to a clinically relevant extent.
Lacosamide did not affect the AUC of midazolam (metabolised by CYP3A4, lacosamide given
200 mg twice a day) but C max of midazolam was slightly increased (30 %). Lacosamide did not affect
the pharmacokinetics of omeprazole (metabolised by CYP2C19 and CYP3A4, lacosamide given
300 mg twice a day).
The CYP2C19 inhibitor omeprazole (40 mg once daily) did not give rise to a clinically significant
change in lacosamide exposure. Thus, moderate inhibitors of CYP2C19 are unlikely to affect systemic
lacosamide exposure to a clinically relevant extent.
Caution is recommended in concomitant treatment with strong inhibitors of CYP2C9 (e.g.
fluconazole) and CYP3A4 (e.g. itraconazole, ketoconazole, ritonavir, clarithromycin), which may lead
to increased systemic exposure of lacosamide. Such interactions have not been established in vivo but
are possible based on in vitro data.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) lead (HOS-085592) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) ritonavir (HOS-084521) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T11:46:00Z · SHA-256 5f9684302e7c8a579e94d70f499a6979b21c5d712f752fe49c5607a3581bef64 · Passage 09bdb85e3781a2bbf9800b7cbb7cfaaa50df0c6d9f79307fa9fb41425f2e39dc · Zeichen 1058–2022 im Abschnitt
Wechselwirkungen · Intelence
INTELENCE 25 mg tablets INTELENCE 100 mg tablets INTELENCE 200 mg tablets · Abschnitt 4.5 · PDF-Seite 13–14
HOS-119744 · Präparat HOS-095005
13
IMMUNOSUPPRESSANTS
Cyclosporin Not studied. Etravirine is expected to decrease Co-administration with
Sirolimus plasma concentrations of cyclosporine, systemic
Tacrolimus sirolimus and tacrolimus. immunosuppressants should
be done with caution because
plasma concentrations of
cyclosporin, sirolimus and
tacrolimus may be affected
when co-administered with
INTELENCE.
NARCOTIC ANALGESICS
Methadone R(-) methadone No changes in methadone
individual dose ranging AUC ↔ 1.06 (0.99-1.13) dosage were required based
from 60 mg to 130 mg Cmin ↔ 1.10 (1.02-1.19) on clinical status during or
once daily Cmax ↔ 1.02 (0.96-1.09) after the period of
S(+) methadone INTELENCE
AUC ↔ 0.89 (0.82-0.96) co-administration.
Cmin ↔ 0.89 (0.81-0.98)
Cmax ↔ 0.89 (0.83-0.97)
etravirine
AUC ↔a
Cmin ↔a
Cmax ↔a
PHOSPHODIESTERASE, TYPE 5 (PDE-5) INHIBITORS
Sildenafil 50 mg single sildenafil Concomitant use of PDE-5
dose AUC ↓ 0.43 (0.36-0.51) inhibitors with INTELENCE
Tadalafil Cmin ND may require dose adjustment
Vardenafil Cmax ↓ 0.55 (0.40-0.75) of the PDE-5 inhibitor to
N-desmethyl-sildenafil attain the desired clinical
AUC ↓ 0.59 (0.52-0.68) effect.
Cmin ND
Cmax ↓ 0.75 (0.59-0.96)
PLATELET AGGREGGATION INHIBITORS
Clopidogrel In vitro data show that etravirine has inhibitory As a precaution it is
properties on CYP2C19. It is therefore possible recommended that
that etravirine may inhibit the metabolism of concomitant use of etravirine
clopidogrel to its active metabolite by such and clopidogrel should be
inhibition of CYP2C19 in vivo. The clinical discouraged.
relevance of this interaction has not been
demonstrated.
PROTON PUMP INHIBITORS
Omeprazole etravirine INTELENCE can be
40 mg once daily AUC ↑ 1.41 (1.22-1.62) co-administered with proton
Cmin ND pump inhibitors without dose
Cmax ↑ 1.17 (0.96-1.43) adjustments.
SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)
Paroxetine paroxetine INTELENCE can be
20 mg once daily AUC ↔ 1.03 (0.90-1.18) co-administered with
Cmin ↓ 0.87 (0.75-1.02) paroxetine without dose
Cmax ↔ 1.06 (0.95-1.20) adjustments.
etravirine
AUC ↔ 1.01 (0.93-1.10)
Cmin ↔ 1.07 (0.98-1.17)
Cmax ↔ 1.05 (0.96-1.15)
a
Comparison based on historic control.
b
Study was conducted with tenofovir disoproxil fumarate 300 mg once daily
Note: In drug-drug interaction studies, different formulations and/or doses of etravirine were used which led to similar
exposures and, therefore, interactions relevant for one formulation are relevant for the other.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) tadalafil (HOS-086316) methadone (HOS-086198) serotonin (HOS-085477) clopidogrel (HOS-087927) tacrolimus (HOS-085202) tenofovir disoproxil fumarate (HOS-110471) sirolimus (HOS-085172) sildenafil (HOS-086162) cyclosporine (HOS-084512) omeprazole (HOS-085912) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-13T16:37:00Z · SHA-256 b6b2c3fd3d600c0f1fd17ddc8f6c1da50bcb8b2181089113d0397c5ec46864c4 · Passage f67f8a9ca44e51616bf8034fedb121fdf73f499dc5e74eb944693ba3f0dbe471 · Zeichen 29319–34348 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-120055 · Präparat HOS-095079
Other concomitant therapies
No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when
rivaroxaban was co-administered with midazolam (substrate of CYP3A4), digoxin (substrate of P-gp),
atorvastatin (substrate of CYP3A4 and P-gp) or omeprazole (proton pump inhibitor). Rivaroxaban
neither inhibits nor induces any major CYP isoforms like CYP3A4.
No clinically relevant interaction with food was observed (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) digoxin (HOS-086172) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage cbce1b4338e29b89b1ba4dfbd0a53a095bd3790454e2e5497dba5dd04ea27b01 · Zeichen 6069–6525 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 36
HOS-120086 · Präparat HOS-095079
Other concomitant therapies
No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when
rivaroxaban was co-administered with midazolam (substrate of CYP3A4), digoxin (substrate of P-gp),
atorvastatin (substrate of CYP3A4 and P-gp) or omeprazole (proton pump inhibitor). Rivaroxaban
neither inhibits nor induces any major CYP isoforms like CYP3A4.
No clinically relevant interaction with food was observed (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) digoxin (HOS-086172) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage cbce1b4338e29b89b1ba4dfbd0a53a095bd3790454e2e5497dba5dd04ea27b01 · Zeichen 6128–6584 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 15 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 63
HOS-120117 · Präparat HOS-095079
Other concomitant therapies
No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when
rivaroxaban was co-administered with midazolam (substrate of CYP3A4), digoxin (substrate of P-gp),
atorvastatin (substrate of CYP3A4 and P-gp) or omeprazole (proton pump inhibitor). Rivaroxaban
neither inhibits nor induces any major CYP isoforms like CYP3A4.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) digoxin (HOS-086172) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 297b3732c3b8702de08c3c846aa51ad9ab1d956532e17c6dfc24385be559bc02 · Zeichen 6352–6731 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.